Practical implication
Sponsors and MAHs must replace the 2021 form with the new 2026 approved form for all six-monthly reports on unapproved therapeutic goods supplied under SAS and CTA schemes.
The Therapeutic Goods Administration (TGA) issued an approval for the 'Six Monthly Report Form - Sponsor' for 2026, effective June 11, 2026. This form replaces the 2021 version and must be used by sponsors for periodic reporting of unapproved therapeutic goods supplied under the Special Access Scheme (SAS) and Clinical Trial Approval (CTA) scheme. MAHs in Australia must adopt the updated form to ensure compliance with TGA reporting formats and timelines.
What changed: TGA approved a new Six Monthly Report Form – Sponsor for 2026, repealing the 2021 version, effective June 11, 2026.
Why it matters: Sponsors and MAHs in Australia must use the updated form for periodic reporting of unapproved therapeutic goods supply; failure to use the correct form may result in non-compliance with TGA reporting obligations.
Practical implication: Sponsors and MAHs must replace the 2021 form with the new 2026 approved form for all six-monthly reports on unapproved therapeutic goods supplied under SAS and CTA schemes.
View original source
Published from the Firecrawl policy change extraction pipeline.
